[go: up one dir, main page]

MX2013013440A - Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos. - Google Patents

Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.

Info

Publication number
MX2013013440A
MX2013013440A MX2013013440A MX2013013440A MX2013013440A MX 2013013440 A MX2013013440 A MX 2013013440A MX 2013013440 A MX2013013440 A MX 2013013440A MX 2013013440 A MX2013013440 A MX 2013013440A MX 2013013440 A MX2013013440 A MX 2013013440A
Authority
MX
Mexico
Prior art keywords
compositions
systems
methods
active agents
suspension
Prior art date
Application number
MX2013013440A
Other languages
English (en)
Inventor
Reinhard Vehring
Michael Steven Hartman
David Lechuga-Ballesteros
Adrian Edward Smith
Vidya B Joshi
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of MX2013013440A publication Critical patent/MX2013013440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/02—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air by heating or combustion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan composiciones, métodos y sistemas para suministro pulmonar o nasal de dos o más agentes activos a través de un inhalador de dosis medida. En una modalidad, las composiciones incluyen un medio de suspensión, partículas de agente activo, y partículas de suspensión, en donde las partículas de agente activo y las partículas de suspensión forman una co-suspensión dentro del medio de suspensión.
MX2013013440A 2011-05-17 2011-05-17 Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos. MX2013013440A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/036868 WO2012158166A1 (en) 2011-05-17 2011-05-17 Compositions, methods & systems for respiratory delivery of two or more active agents

Publications (1)

Publication Number Publication Date
MX2013013440A true MX2013013440A (es) 2014-06-05

Family

ID=47177229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013440A MX2013013440A (es) 2011-05-17 2011-05-17 Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.

Country Status (14)

Country Link
EP (1) EP2709447A4 (es)
JP (1) JP2014518871A (es)
KR (1) KR20140032404A (es)
CN (1) CN103687483A (es)
AU (1) AU2011368334A1 (es)
BR (1) BR112013029507A2 (es)
CA (1) CA2835927A1 (es)
EA (1) EA201490991A1 (es)
IL (1) IL229260A0 (es)
MX (1) MX2013013440A (es)
PH (1) PH12013502270A1 (es)
RU (1) RU2013155903A (es)
SG (1) SG194896A1 (es)
WO (1) WO2012158166A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2435024T3 (pl) 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HK1215545A1 (zh) 2013-01-31 2016-09-02 Circassia Limited 适用於吸入治疗的包含多组分结晶颗粒的药物组合物
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN105392471A (zh) * 2013-05-22 2016-03-09 珍珠治疗公司 用于呼吸递送三种或更多种活性剂的组合物、方法和系统
TN2016000262A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3191081B1 (en) 2014-09-09 2020-03-25 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
US20180147161A1 (en) * 2015-05-01 2018-05-31 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
CN105125542A (zh) * 2015-08-23 2015-12-09 杭州紫金医药科技有限公司 含噻托溴铵和福莫特罗的药物组合物及其用途和制剂
CN106880636A (zh) * 2015-12-15 2017-06-23 天津金耀集团有限公司 一种环索奈德单方和复方干粉吸入剂组合物
CN106880637B (zh) * 2015-12-15 2021-01-29 天津金耀集团有限公司 一种环索奈德福莫特罗噻托溴铵复方干粉吸入剂组合物
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2020100040A1 (en) * 2018-11-12 2020-05-22 3M Innovative Properties Company Umeclidinium and vilanterol formulation and inhaler
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
WO2022148418A1 (zh) * 2021-01-08 2022-07-14 江苏恒瑞医药股份有限公司 可通过定量吸入器递送的药物组合物
PT4175619T (pt) * 2021-07-09 2024-06-06 AstraZeneca Pharmaceuticals LP Composições, métodos e sistemas para administração de fármacos em aerossol
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100589926B1 (ko) * 1997-09-29 2006-06-15 넥타르 테라퓨틱스 천공된 미립자 및 사용 방법
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL2435024T3 (pl) * 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy

Also Published As

Publication number Publication date
CA2835927A1 (en) 2012-11-22
SG194896A1 (en) 2013-12-30
PH12013502270A1 (en) 2014-01-27
AU2011368334A1 (en) 2013-11-21
CN103687483A (zh) 2014-03-26
EA201490991A1 (ru) 2014-09-30
BR112013029507A2 (pt) 2019-09-24
RU2013155903A (ru) 2015-06-27
WO2012158166A1 (en) 2012-11-22
IL229260A0 (en) 2014-01-30
EP2709447A4 (en) 2014-10-22
KR20140032404A (ko) 2014-03-14
JP2014518871A (ja) 2014-08-07
EP2709447A1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
MX2013013440A (es) Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
MX337126B (es) Administracion respiratoria de agentes activos.
CY1121373T1 (el) Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη
NI201500163A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
CL2014002808A1 (es) Dispositivo de inhalacion plegable para usar con un dispensador de inhalador de dosis medida, dicho dispositivo comprende un miembro de la extremidad de salida incluyendo una boquilla, un miembro de la extremidad de entrada incluyendo un orificio de entrada, y un miembro de manguito tubular; metodo para administrar una dosis de un medicamento; metodo para formar un dispositivo de inhalacion plegable.
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
MX373138B (es) Inhalador de polvo seco y método de uso.
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
CL2011002002A1 (es) Uso de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1- hidroxietil)-8-hidroxiquinolin-2-(1h)-ona, en forma de racemato, estereoisomero o mezclas de esteroisomeros o una sal o solvato del mismo para preparar un medicamento util para tratar una enfermedad pulmonar.
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
AR088273A1 (es) Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida
BR112017006816A2 (pt) dispositivo de inalação.
DOP2013000262A (es) Composiciones, métodos y sistemas para el suministro respiratorio de dos o mas agentes activos
CR20130589A (es) Composiciones, métodos y sitemas para administracion/suministro respiratorio de dos o más agentes activos
ECSP13013082A (es) Composiciones, métodos y sistemas para administración respiratoria de dos o más agentes activos
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
AR093601A1 (es) Composiciones, metodos y sistemas para administracion respiratoria de dos o mas agentes activos
MX390789B (es) Composición farmacéutica de dosis fija que comprende mometasona y azelastina.
UA109530C2 (uk) Композиції, способи та системи для доставки респіраторним шляхом двох чи більше активних агентів